Gestonorone Caproate

01/01/1971 - "Evaluation of Depostat in prostatic adenoma on the ground of clinical and sphincterotonometric studies."
07/16/1984 - "[Treatment of benign prostatic hypertrophy with gestonorone caproate]."
09/01/1980 - "[Results of treating prostatic adenoma with Depostat]."
09/14/1973 - "Depostat for benign prostatic hyperplasia?"
02/01/1972 - "Clinical trial of gestronol hexanoate (SH582) in benign prostatic hypertrophy."

01/01/1977 - "A study was carried out in 30 male patients with benign prostate hyperplasia to assess the effectiveness of treatment with a progestational agent, gestonorone caproate (200 mg), given intramucularly every 7 days over a period of 2 to 3 months. "

01/01/1972 - "20 patients with endometrial carcinoma received injections of 17-hydroxynorprogesterone capronate (Depostat, average dose 1000 mg) within 14 days after a 1st abrasion. "

02/01/1978 - "1. The value of progestogen therapy in the prevention of postmenopausal bone loss was assessed in 30 women, by a preliminary randomized controlled trial of gestronol or mestranol, in comparison with a placebo. "

07/01/1979 - "The treatment of advanced cystadenocarcinoma of the ovary with gestronol and continuous oral cyclophosphamide."
07/01/1979 - "Fifty-four patients with advanced cystadenocarcinoma of the ovary were treated with gestronol (Depostat), 200 mg/week, by intramuscular injection and continuous oral cyclophosphamide, the dose of the latter being varied to maintain the patient's white cell count at about 1.5 x 10(9)/l. "